Beth Coyle

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8597006/publications.pdf

Version: 2024-02-01

54	9,380	394421	214800
papers	citations	19 h-index	47 g-index

55	55	55	15801
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018, 7, 1535750.	12.2	6,961
2	Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease. Journal of Clinical Oncology, 2010, 28, 3061-3068.	1.6	558
3	Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature, 2010, 466, 632-636.	27.8	324
4	In vitro models of medulloblastoma: Choosing the right tool for the job. Journal of Biotechnology, 2016, 236, 10-25.	3.8	165
5	Pediatric Ependymoma: Biological Perspectives. Molecular Cancer Research, 2009, 7, 765-786.	3.4	162
6	Pendred syndrome (goitre and sensorineural hearing loss) maps to chromosome 7 in the region containing the nonsyndromic deafness gene DFNB4. Nature Genetics, 1996, 12, 421-423.	21.4	146
7	Copy Number Gain of 1q25 Predicts Poor Progression-Free Survival for Pediatric Intracranial Ependymomas and Enables Patient Risk Stratification: A Prospective European Clinical Trial Cohort Analysis on Behalf of the Children's Cancer Leukaemia Group (CCLG), SociÃ©tÃ© FranÃ§aise d'Oncologie PÃ©diatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Clinical Cancer Research, 2012, 18, 2001-2011.	7.0	111
8	Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. Neuro-Oncology, 2011, 13, 212-222.	1.2	103
9	Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. Neuro-Oncology, 2008, 10, 675-689.	1.2	90
10	Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. Neuro-Oncology, 2011, 13, 866-879.	1.2	67
11	Pediatric brain tumor cancer stem cells: cell cycle dynamics, DNA repair, and etoposide extrusion. Neuro-Oncology, 2011, 13, 70-83.	1.2	60
12	A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells. Cellular Oncology (Dordrecht), 2018, 41, 319-328.	4.4	53
13	CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma. Acta Neuropathologica, 2012, 124, 99-110.	7.7	51
14	Overcoming multiple drug resistance mechanisms in medulloblastoma. Acta Neuropathologica Communications, 2014, 2, 57.	5.2	49
15	Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death. Acta Neuropathologica, 2012, 123, 711-725.	7.7	38
16	Characterization of the Transforming Growth Factor-Î²1-induced Apoptotic Transcriptome in FaO Hepatoma Cells. Journal of Biological Chemistry, 2003, 278, 5920-5928.	3.4	34
17	Histone Deacetylase Inhibition Attenuates Cell Growth with Associated Telomerase Inhibition in High-Grade Childhood Brain Tumor Cells. Molecular Cancer Therapeutics, 2010, 9, 2568-2581.	4.1	34
18	Genomic structure of the human congenital chloride diarrhea (CLD) gene. Gene, 1998, 214, 87-93.	2.2	33

#	Article	IF	Citations
19	Investigation of chromosome 1q reveals differential expression of members of the S100 family in clinical subgroups of intracranial paediatric ependymoma. British Journal of Cancer, 2008, 99, 1136-1143.	6.4	30
20	3D spheroid models of paediatric SHH medulloblastoma mimic tumour biology, drug response and metastatic dissemination. Scientific Reports, 2021, 11, 4259.	3.3	20
21	Concurrence of Pendred Syndrome, Autoimmune Thyroiditis, and Simple Goiter in One Family. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2736-2738.	3.6	19
22	WNT/Î²-catenin pathway activation in Myc immortalised cerebellar progenitor cells inhibits neuronal differentiation and generates tumours resembling medulloblastoma. British Journal of Cancer, 2012, 107, 1144-1152.	6.4	19
23	Early Drug Safety Evaluation: Biomarkers, Signatures, and Fingerprints. Drug Metabolism Reviews, 2003, 35, 269-275.	3.6	18
24	ABCB1 in children's brain tumours. Biochemical Society Transactions, 2015, 43, 1018-1022.	3.4	18
25	Regulation of apoptosis by peroxisome proliferators. Toxicology Letters, 2004, 149, 37-41.	0.8	17
26	Pediatric high-grade glioma: identification of poly(ADP-ribose) polymerase as a potential therapeutic target. Neuro-Oncology, 2011, 13, 1171-1177.	1.2	17
27	PI3K Pathway Activation Provides a Novel Therapeutic Target for Pediatric Ependymoma and Is an Independent Marker of Progression-Free Survival. Clinical Cancer Research, 2013, 19, 6450-6460.	7.0	17
28	Novel strategy to study gene expression and function in developing cerebellar granule cells. Journal of Neuroscience Methods, 2004, 132, 149-160.	2.5	16
29	RASSF1A and the BH3-only mimetic ABT-737 promote apoptosis in pediatric medulloblastoma cell lines. Neuro-Oncology, 2011, 13, 1265-1276.	1.2	15
30	The role of the WNT/Î²-catenin pathway in central nervous system primitive neuroectodermal tumours (CNS PNETs). British Journal of Cancer, 2013, 108, 2130-2141.	6.4	15
31	Chemosensitization of Temozolomide-Resistant Pediatric Diffuse Midline Glioma Using Potent Nanoencapsulated Forms of a N(3)-Propargyl Analogue. ACS Applied Materials & Interfaces, 2021, 13, 35266-35280.	8.0	15
32	Medulloblastoma and ependymoma cells display increased levels of 5-carboxylcytosine and elevated TET1 expression. Clinical Epigenetics, 2017, 9, 18.	4.1	14
33	Thyroid peroxidase: evidence for disease gene exclusion in Pendred's syndrome. Clinical Endocrinology, 1996, 44, 441-446.	2.4	13
34	A role for ABCB1 in prognosis, invasion and drug resistance in ependymoma. Scientific Reports, 2019, 9, 10290.	3.3	13
35	Establishing an In Vitro 3D Spheroid Model to Study Medulloblastoma Drug Response and Tumor Dissemination. Current Protocols, 2022, 2, e357.	2.9	9
36	Data on the number and frequency of scientific literature citations for established medulloblastoma cell lines. Data in Brief, 2016, 9, 696-698.	1.0	7

#	Article	IF	Citations
37	Wilms' Tumor Protein 1 and Enzymatic Oxidation of 5-Methylcytosine in Brain Tumors: Potential Perspectives. Frontiers in Cell and Developmental Biology, 2018, 6, 26.	3.7	7
38	Strategies to investigate gene expression and function in granule cells. Cerebellum, 2005, 4, 271-278.	2.5	6
39	Leptomeningeal malignancy of childhood: sharing learning between childhood leukaemia and brain tumour trials. The Lancet Child and Adolescent Health, 2020, 4, 242-250.	5.6	6
40	<scp>3D</scp> hydrogels reveal medulloblastoma subgroup differences and identify extracellular matrix subtypes that predict patient outcome. Journal of Pathology, 2021, 253, 326-338.	4.5	6
41	Concurrence of Pendred Syndrome, Autoimmune Thyroiditis, and Simple Goiter in One Family. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2736-2738.	3.6	6
42	Immunostaining for DNA Modifications: Computational Analysis of Confocal Images. Journal of Visualized Experiments, 2017, , .	0.3	5
43	BLBP Is Both a Marker for Poor Prognosis and a Potential Therapeutic Target in Paediatric Ependymoma. Cancers, 2021, 13, 2100.	3.7	5
44	Y-Box Binding Protein-1: A Neglected Target in Pediatric Brain Tumors?. Molecular Cancer Research, 2021, 19, 375-387.	3.4	4
45	ABCB1 inhibition provides a novel therapeutic target to block TWIST1-induced migration in medulloblastoma. Neuro-Oncology Advances, 2021, 3, vdab030.	0.7	2
46	Long-term exposure to irinotecan reduces cell migration in glioma cells. Journal of Neuro-Oncology, 2016, 127, 455-462.	2.9	1
47	MBRS-46. JERANTININE: A NOVEL TUMOUR-SPECIFIC ALKALOID FOR THE TREATMENT OF PAEDIATRIC MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i138-i138.	1.2	1
48	MBRS-49. USING SENSITIVE MAGNETIC RESONANCE IMAGING TECHNIQUES TO IMPROVE THE RISK STRATIFICATION OF PATIENTS WITH METASTATIC MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i138-i139.	1.2	0
49	MBRS-39. TWIST1 PLAYS A REGULATORY ROLE IN MEDULLOBLASTOMA METASTASIS. Neuro-Oncology, 2018, 20, i136-i137.	1.2	0
50	MBRS-47. ESTABLISHMENT OF A 3D SPHEROID-BASED MODEL OF MEDULLOBLASTOMA THAT RECAPITULATES TUMOUR GROWTH, DRUG RESPONSE AND MIGRATION. Neuro-Oncology, 2018, 20, i138-i138.	1.2	0
51	MBRS-28. EXOSOMES DRIVE MEDULLOBLASTOMA METASTASIS IN A MMP2 AND EMMPRIN DEPENDENT MANNER. Neuro-Oncology, 2020, 22, iii403-iii403.	1.2	0
52	MBRS-27. EXOSOMES CARRY DISTINCT miRNAs THAT DRIVE MEDULLOBLASTOMA PROGRESSION. Neuro-Oncology, 2020, 22, iii403-iii403.	1.2	0
53	MBRS-42. YB-1 - A NOVEL THERAPEUTIC TARGET IN HIGH-RISK MEDULLOBLASTOMA?. Neuro-Oncology, 2020, 22, iii405-iii405.	1.2	0
54	DDRE-37. YB-1 AS A BIOMARKER FOR DRUG RESISTANCE AND TUMOUR PROGRESSION IN MEDULLOBLASTOMA. Neuro-Oncology, 2021, 23, vi82-vi82.	1.2	0